The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis

BACKGROUND: CT‐P13, a biosimilar of the reference product infliximab, has been approved for the treatment of ulcerative colitis on the basis of the results of trials conducted in patients with spondyloarthritis and rheumatoid arthritis. AIM: To compare the effectiveness and safety of CT‐P13 and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Antoine, Rudant, Jérémie, Drouin, Jérôme, Coste, Joël, Carbonnel, Franck, Weill, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Infliximab Biosimilar in Ulcerative Colitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767082/
https://www.ncbi.nlm.nih.gov/pubmed/31115919
http://dx.doi.org/10.1111/apt.15323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767082/
https://www.ncbi.nlm.nih.gov/pubmed/31115919
http://dx.doi.org/10.1111/apt.15323

Ejemplares similares